thalidomide has been researched along with Inflammatory Response Syndrome, Systemic in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide treatment decreased TNF and IL-1 significantly in both experimental groups at both the points (P<0." | 1.35 | Thalidomide decreases the plasma levels of IL-1 and TNF following burn injury: is it a new drug for modulation of systemic inflammatory response. ( Eski, M; Ifran, A; Sahin, I; Sengezer, M; Serdar, M, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Panousis, K | 1 |
| Nikolaou, VS | 1 |
| Tsaganos, T | 1 |
| Lallos, S | 1 |
| Giamarellos-Bourboulis, EJ | 1 |
| Efstathopoulos, N | 1 |
| Eski, M | 1 |
| Sahin, I | 1 |
| Sengezer, M | 1 |
| Serdar, M | 1 |
| Ifran, A | 1 |
2 other studies available for thalidomide and Inflammatory Response Syndrome, Systemic
| Article | Year |
|---|---|
Thalidomide prolongs survival after experimental musculoskeletal injury, through an effect on mononuclear apoptosis.
Topics: Animals; Apoptosis; Drug Evaluation, Preclinical; Femoral Fractures; Fractures, Open; Immunosuppress | 2014 |
Thalidomide decreases the plasma levels of IL-1 and TNF following burn injury: is it a new drug for modulation of systemic inflammatory response.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Burns; Drug Evaluation, Preclinical; Interleukin-1 | 2008 |